NeuroSense Therapeutics Ltd. Logo

NeuroSense Therapeutics Ltd.

A late-clinical stage company developing drugs for neurodegenerative diseases like ALS.

NRSN | US

Overview

Corporate Details

ISIN(s):
IL0011809592 (+1 more)
LEI:
Country:
United States of America
Address:
11 HAMENOFIM ST., 4672562 HERZLIYA

Description

NeuroSense Therapeutics Ltd. is a late-clinical stage drug development company focused on discovering and developing treatments for severe neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). The company's strategy is to create combined therapies that target multiple pertinent mechanisms involved in these complex conditions. Its lead drug candidate, PrimeC, is a unique fixed-dose combination of ciprofloxacin and celecoxib. Following a successful Phase 2b clinical trial (PARADIGM) that demonstrated a significant impact on slowing disease progression, NeuroSense is advancing PrimeC into a pivotal Phase 3 study. PrimeC has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company is also exploring therapies for other neurodegenerative diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all NeuroSense Therapeutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NeuroSense Therapeutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NeuroSense Therapeutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Aldeyra Therapeutics, Inc. Logo
Develops medications for immune-mediated ocular and systemic diseases.
United States of America
ALDX
Alector, Inc. Logo
Clinical-stage biotech using immuno-neurology to treat neurodegenerative diseases.
United States of America
ALEC
ALK-Abelló Logo
A pharmaceutical company specializing in allergy prevention, diagnosis, and treatment.
Denmark
ALK
Alkaloid AD Logo
Manufactures generic pharmaceuticals, cosmetics, and chemical products.
North Macedonia
ALK
Alkermes plc. Logo
Develops and commercializes medicines for central nervous system (CNS) diseases.
United States of America
ALKS
Allarity Therapeutics, Inc. Logo
A clinical-stage biopharma using diagnostics to develop targeted cancer therapies.
United States of America
ALLR
ALLERGY THERAPEUTICS PLC Logo
Immunology company developing aluminum-free vaccines and therapies for allergies.
United Kingdom
AGY
Alligator Bioscience Logo
Clinical-stage biotech developing tumor-directed immuno-oncology antibody drugs.
Sweden
ATORX
Allogene Therapeutics, Inc. Logo
Develops off-the-shelf allogeneic CAR T therapies for cancer and autoimmune diseases.
United States of America
ALLO
Almirall S.A. Logo
Global biopharmaceutical company specializing in medical dermatology and skin health.
Spain
ALM

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.